Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iHuman (IH) Cash & Equivalents (2020 - 2025)

iHuman has reported Cash & Equivalents over the past 6 years, most recently at $162.3 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 3.79% to $162.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162.3 million through Dec 2025, up 3.79% year-over-year, with the annual reading at $164.6 million for FY2025, 6.96% up from the prior year.
  • Cash & Equivalents was $162.3 million for Q4 2025 at iHuman, up from $156.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $168.6 million in Q4 2023 and troughed at $133.8 million in Q4 2021.
  • The 5-year median for Cash & Equivalents is $156.4 million (2024), against an average of $153.7 million.
  • Biggest five-year swings in Cash & Equivalents: grew 14.19% in 2023 and later dropped 7.24% in 2024.
  • Tracing IH's Cash & Equivalents over 5 years: stood at $133.8 million in 2021, then rose by 10.35% to $147.6 million in 2022, then rose by 14.19% to $168.6 million in 2023, then decreased by 7.24% to $156.4 million in 2024, then grew by 3.79% to $162.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $162.3 million, $156.4 million, and $168.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.